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The role of cathepsin B, a lysosomal protease impli-
cated in amyloid-b (Ab1-42) metabolism, in Alz-
heimer’s disease remains controversial. In this issue
of Neuron, Mueller-Steiner et al. manipulate the ex-
pression of cathepsin B in aged APP transgenic
mice, observing that increased expression degrades
preformed oligomeric and fibrillar amyloid, while
inactivation accelerates b-amyloidosis.
Amyloid-b protein (Ab) is a 40–42 amino acid peptide,
accumulating in plaques and blood vessels of Alz-
heimer’s disease (AD) patients. Although Ab peptides
are normally cleaved out of a larger amyloid precursor
protein (APP) by endopeptidase ‘‘secretase’’ enzymes
and rapidly released and cleared in soluble form, in
AD, Ab peptides accumulate extracellularly as prote-
ase-resistant fibrillar aggregates with b pleated sheet
conformation. The longer 42 amino acid form (Ab1-42)
has two additional hydrophobic amino acids making it
‘‘stickier,’’ causing it to aggregate much more rapidly
than the 40 amino acid form and even to accumulate
within neurons, an event that may contribute to neuro-
toxicity. Ab1-42 is implicated in AD pathogenesis be-
cause early-onset familial AD can be caused by many
different mutations with the common property of in-
creasing the production of Ab1-42. However, the major-
ity of AD cases are late onset and of as yet unknown
origin.
One contributing and possibly causal factor in Ab ac-
cumulation in late-onset AD is an aging- or disease-re-
lated decline in the proteases that normally clear soluble
Ab species. Several proteases have already been identi-
fied that contribute to the normal rapid clearance of sol-
uble Ab. These include insulin-degrading enzyme (IDE),
neprilysin (Nep), endothelin-converting enzyme (ECE),
and plasmin (Eckman and Eckman, 2005). However,
once the b sheet Ab fibrils have formed, they become re-
sistant to these important normal clearance mecha-
nisms, causing amyloid to accumulate exponentially.
In the current issue of Neuron, Mueller-Steiner and
colleagues (Mueller-Steiner et al., 2006) at the Gladstone
Institute, UCSF, unveil compelling and novel evidence
that the endosomal/lysosomal protease cathepsin B
(CatB) normally degrades Ab1-42, including fibrillar Ab
aggregates. Previous research had suggested that
CatB might function as a ‘‘secretase’’ and help cleave
APP to Ab. However, when the Gladstone researchers
tested the hypothesis by expressing APP in CatB null
mice, there was no impact on any APP secretase prod-
ucts. Rather than altering APP processing, loss of CatB
resulted in increased amyloid plaque load and increased
Ab1-42 to total Ab ratios determined by ELISA. The in-
creases in amyloid were accompanied by reduced hip-
pocampal dentate gyrus calbindin, a marker which the
authors have previously found to reflect neurodegener-
ation in their APP transgenic mice. CatB was localizedextracellularly to plaques and internally to plaque-asso-
ciated dystrophic neurites, reactive astrocytes, and mi-
croglia (Figure 1). These results are consistent with re-
ports of increased neuronal CatB and extracellular
CatB in plaques in AD brain (Nixon and Cataldo, 2006).
Within the Tg+ mouse neurons, this Cat was found in
lysosomes (as expected). Further, Ab1-42 levels were
decreased in primary neurons overexpressing virally
directed CatB, suggesting that intraneuronal Ab1-42
accumulating in the endosomal/lysosomal system
might be a CatB target. Although the mouse model
used in the present study has not been reported to accu-
mulate high levels of intraneuronal Ab, intraneuronal Ab
accumulation has been linked to neurodegeneration
(Takahashi et al., 2004) and cognitive deficits (Billings
et al., 2005).
CatB Nips at Ab Better Than Nep
Analysis by SELDI-TOF mass spectrometry demon-
strated that the in vitro carboxypeptidase activity of
CatB nipped at the Ab1-42 C terminus, generating the
less amyloidogenic C-terminally truncated Ab1-40 and
Ab1-38. This result explains some selectivity of CatB
for long Ab. Ab1-33 was also generated, presumably
by endopeptidase activity. Most significantly, poten-
tially neurotoxic oligomeric, protofibrillar, and even fi-
brillar aggregates were equally readily cleaved by
CatB, producing the same products. While the activity
was higher at pH 6.0, where it might be in intracellular
compartments, CatB also effectively degraded all of
the Ab assemblies at neutral pH, suggesting that it can
work on extracellular deposits. Consistent with this ex-
pectation, expression of stereotaxically injected lentivi-
ral CatB for 28 days in aged plaque-bearing APP trans-
genic mice cleared preformed Ab deposits, including
thioflavin S-positive plaques, which are known to con-
tain masses of protease-resistant fibrillar Ab. In con-
trast, thioflavin S plaques remained unchanged by lenti-
viral expression of neprilysin (Nep), which only cleared
diffuse Ab deposits compared to viral vector alone.
Thus, CatB in mouse was a better Ab degrader than
Nep, although Nep can effectively degrade small Ab
oligomers like dimers that can compromise synaptic
function (Huang et al., 2006). In view of the widely held
belief that the neurotoxic properties of aggregated Ab
assemblies actually cause AD, the identification of a ma-
jor protease responsible for their intracellular and extra-
cellular clearance is an exciting result and full of prom-
ise. One of the few other options might be to increase
matrix metalloproteinase-9, also very recently identified
as a fibril protease (Yan et al., 2006). While it is likely not
possible to virally express CatB in humans, there may be
other ways to increase CatB expression. For example,
the authors observed that microglia secrete abundant
CatB. This may be regulated by their activation state,
which, for example, can be upregulated by the amyloid
vaccine or anti-amyloid antibodies, currently one of
the most effective methods of reducing preformed thio-
flavin S-labeled amyloid plaques (Bard et al., 2003). One
might consider expressing exogenous CatB in grafted
bone marrow cells, which have been shown to migrate
Inherited Neuropathies:
New Genes Don’t
Fit Old Models
Mutations in GARS cause dominantly inherited neu-
ropathies in humans.GARS encodes glycyl-tRNA syn-
thetase, the enzyme that couples glycine to its tRNA. In
this issue of Neuron, Seburn et al. have identified and
characterized a mutant mouse with a dominantly in-
herited axonal neuropathy caused by a Gars mutation
that is inferred to have a gain of function.
In 1886, Charcot, Marie, and Tooth described patients
who are now understood as having a dominantly in-
herited neuropathy that affects myelinated motor and
sensory axons in a length-dependent manner. This dis-
order is usually called Charcot-Marie-Tooth disease, or
simply CMT, and is one of the most common inherited
neurological diseases (Lupski and Garcia, 2001; Shy
et al., 2005; Wrabetz et al., 2004). Like most kinds of neu-
ropathy, CMT is characterized by progressive dysfunc-
tion that is related to the length of the affected axons.
The longest sensory and motor axons are affected first
and are more affected over time. This progressive,
length-dependent dying back of motor and sensory
axons produces the classic clinical picture of distally
accentuated weakness, atrophy, and sensory loss.
By 1980, a few different kinds of CMT were clinically
recognized. The demyelinating form was termed CMT1
and is characterized by slowed nerve conduction veloc-
ities and evidence of demyelination and remyelination in
nerve biopsies. The neuronal/axonal form was termed
CMT2, characterized by relatively normal conduction
velocities and axonal loss but not demyelination/remye-
lination in nerve biopsies. The more severe kinds of de-
myelinating neuropathy that start in infancy or childhood
retained different names (congenital hypomyelinating
neuropathy or Dejerine-Sottas neuropathy, respec-
tively), and their relationship to CMT was not under-
stood. The terms hereditary motor neuropathies and
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672to plaques (Simard et al., 2006). However, there is rea-
son to be cautious about overexpression of CatB, which
has been reported to contribute to neurotoxic effects of
microglia (Gan et al., 2004; Kingham and Pocock, 2001).
Of course, there may be other ways to increase intracel-
lular CatB expression with small molecules. Whether or
not the new findings lead to CatB-based therapeutics,
the evidence for this normal clearance tale for Ab aggre-
gates is clearly an important new chapter for the AD re-
search field. And with any luck, this will not end as just
a Cat in mouse story.
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Figure 1. Schematic Diagram Showing the Role of Cathepsin B in
Amyloid Clearance
Mueller-Steiner et al. demonstrate that cathepsin B (CatB) can clear
fibrillar amyloid-b. CatB can be secreted (arrows) into plaques
(green star) and promote the degradation of extracellular amyloid-
b. A major potential source of CatB in plaques may be microglia (or-
ange), which secrete avidly in vitro, but other cell types (astrocytes,
blue top left) and neurons (gray, right) may also contribute CatB to
plaques. The green circles with ‘‘B’’ represent endosomes or lyso-
somes containing CatB, where it may degrade intracellular Ab. It is
unclear whether CatB secreted from neurons is primarily dendritic
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